中生北控生物科技股票讨论区

Investors expect the company to underperform the broader industry, leading to a low P/S ratio. The declining revenues and industry's projected growth could further decrease the ratio, potentially disappointing shareholders. Shareholders accept the current low P/S ratio, expecting no pleasant surprises in future revenue.